Rethinking Neurodegenerative
Disease Treatment
Transforming ALS and Alzheimer Disease Treatment Through
Precision Neuroinflammation Targeting
PhenoNet is a clinical-stage biotechnology company developing next-generation therapies for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), and related neurodegenerative disorders. Our mission is to deliver safe, effective, and personalized treatments that target the root causes of disease progression—focusing on neuroinflammation and patient-specific biology.
Rather than relying on one-size-fits-all solutions, PhenoNet pioneers a new class of therapeutics tailored to individual genetic and clinical profiles. Breakthroughs in genomics, biomarker-led patient stratification, and translational neuroscience drive our science.
PhenoNet’s two lead drug families are designed to address the molecular complexity of neurodegenerative conditions. These multi-functional compounds aim to slow or halt disease progression by targeting chronic neuroinflammation and supporting neuronal repair—offering renewed hope for patients and caregivers.
PhenoNet is a clinical-stage biotechnology company developing next-generation therapies for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), and related neurodegenerative disorders. Our mission is to deliver safe, effective, and personalized treatments that target the root causes of disease progression—focusing on neuroinflammation and patient-specific biology.
Rather than relying on one-size-fits-all solutions, PhenoNet pioneers a new class of therapeutics tailored to individual genetic and clinical profiles. Breakthroughs in genomics, biomarker-led patient stratification, and translational neuroscience drive our science.
PhenoNet’s two lead drug families are designed to address the molecular complexity of neurodegenerative conditions. These multi-functional compounds aim to slow or halt disease progression by targeting chronic neuroinflammation and supporting neuronal repair—offering renewed hope for patients and caregivers.
Disclaimer
This communication contains forward-looking statements, except for information related to current FDA authorizations. Actual results may vary due to clinical trial outcomes, regulatory decisions, financial circumstances, and competitive developments.
Transforming ALS and Alzheimer Disease Treatment Through Precision Neuroinflammation Targeting
PhenoNet is a clinical-stage biotechnology company developing next-generation therapies for Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD), and related neurodegenerative disorders. Our mission is to deliver safe, effective, and personalized treatments that target the root causes of disease progression—focusing on neuroinflammation and patient-specific biology.
Rather than relying on one-size-fits-all solutions, PhenoNet pioneers a new class of therapeutics tailored to individual genetic and clinical profiles. Breakthroughs in genomics, biomarker-led patient stratification, and translational neuroscience drive our science.
PhenoNet’s two lead drug families are designed to address the molecular complexity of neurodegenerative conditions. These multi-functional compounds aim to slow or halt disease progression by targeting chronic neuroinflammation and supporting neuronal repair—offering renewed hope for patients and caregivers.
Disclaimer
This communication contains forward-looking statements, except for information related to current FDA authorizations. Actual results may vary due to clinical trial outcomes, regulatory decisions, financial circumstances, and competitive developments.
